<DOC>
	<DOC>NCT01464437</DOC>
	<brief_summary>This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group, fixed dose study. AMG 151 will be evaluated in subjects with type 2 diabetes treated with metformin for at least 3 months prior to randomization.</brief_summary>
	<brief_title>AMG 151 Amgen Protocol Number 20100761</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 18 to 75 years, inclusive Diagnosis of type 2 diabetes mellitus HbA1c levels 7.5% to 11.0%, inclusive, at screening Fasting Cpeptide levels ≥ 0.2 nmol/L at screening BMI ≥ 25 to &lt; 45 kg/m2 at screening Treated with metformin monotherapy for at least 3 months prior to randomization; the metformin dose must be ≥ 850 mg daily for at least 2 months immediately prior to randomization If a subject is being treated for hyperlipidemia or hypertension they should be on stable medication for 30 days before randomization Subject has provided informed consent. History of type 1 diabetes History of significant weight gain or loss (&gt; 10%) during the 4 weeks before randomization Use of any weight loss medication (over the counter or prescription) within 60 days of randomization Use of any oral or injectable antihyperglycemic medication (other than metformin) within 3 months prior to randomization Use of chronic and/or continuous insulin administration for &gt; 15 days in an outpatient setting to achieve and maintain glycemic control prior to randomization Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months Have had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study, or currently diagnosed as having hypoglycemia unawareness Evidence of active infections that can interfere with the study Presence of clinically significant organ system disease that is not stabilized or may interfere with the study Currently receiving immunosuppressive therapy History of positive HIV, chronic hepatitis B or C, or cirrhosis Have symptomatic congestive heart failure or a history of myocardial infarction, unstable angina, or decompensated congestive heart failure or stroke in the past 6 months prior to screening. History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption Any finding on the screening ECG that in the opinion of the investigator requires further cardiovascular evaluation Poorly controlled hypertension defined as diastolic pressure &gt; 100 mm Hg or systolic pressure &gt; 160 mm Hg (assessed on two separate occasions during the screening period) Malignancy (other than resected cutaneous basal or cutaneous squamous cell carcinoma, or treated in situ cervical cancer considered cured) within 5 years of screening visit (if a malignancy occurred &gt; 5 years ago, subject is eligible with documentation of diseasefree state since treatment) Use of known inhibitors or inducers of CYP3A4 are not permitted 30 days prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>diabetes</keyword>
	<keyword>mellitus</keyword>
	<keyword>metformin</keyword>
</DOC>